2022
Diabetes medications and risk of HCC
Torres M, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022, 76: 1880-1897. PMID: 35239194, PMCID: PMC9790535, DOI: 10.1002/hep.32439.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetes mellitusLiver diseaseRisk of HCCDiabetic medicationsDiabetes mellitusGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsCotransporter 2 inhibitorsAchievement of euglycemiaInsulin-sensitizing activityLiver cancer tumorigenesisDiabetes medicationsDrug armamentariumInsulin resistanceReceptor agonistRisk factorsInsulin secretionCurrent evidenceNew agentsCancer tumorigenesisGlucose absorptionEndocrinology perspectiveHepatic carcinogenesis
1998
Purinergic regulation of acid/base transport in human and rat biliary epithelial cell lines
Zsembery Á, Spirlì C, Granato A, LaRusso N, Okolicsanyi L, Crepaldi G, Strazzabosco M. Purinergic regulation of acid/base transport in human and rat biliary epithelial cell lines. Hepatology 1998, 28: 914-920. PMID: 9755225, DOI: 10.1002/hep.510280403.Peer-Reviewed Original ResearchConceptsCholangiocyte cell lineNHE activityPurinergic agonistsBiliary epithelial cell lineExtracellular ATPCell linesIntracellular cyclic adenosine monophosphate (cAMP) concentrationsBiliary HCO3- secretionRat cholangiocyte cell lineCyclic adenosine monophosphate concentrationsAdenosine receptor agonistsBiliary epithelial cellsMz-ChA-1 cellsAdenosine monophosphate concentrationsSynergistic stimulatory effectApical administrationEpithelial cell lineReceptor agonistP2Y2 receptorPurinergic receptorsBile volumePharmacological profileApical Cl- channelsBasolateral administrationHCO3- secretion